MENU
+Compare
PBE
ETF ticker: NYSE ARCA
AS OF
Jan 17 closing price
Price
$67.68
Change
-$0.16 (-0.24%)
Net Assets
250.32M

PBE stock forecast, quote, news & analysis

Category: @Health
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for PBE with price predictions
Jan 08, 2025

PBE's Stochastic Oscillator stays in overbought zone for 2 days

Expect a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PBE broke above its upper Bollinger Band on January 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PBE entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PBE's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on PBE as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBE just turned positive on January 06, 2025. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

PBE moved above its 50-day moving average on January 08, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 19.97B. The market cap for tickers in the group ranges from 510.52M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is EYPT at 510.52M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was -0%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was -1%. ITCI experienced the highest price growth at 33%, while MYGN experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 73
P/E Growth Rating: 61
Price Growth Rating: 56
SMR Rating: 74
Profit Risk Rating: 55
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com